The introduction of nicotinamide as being a nicotine alternative in e-cigarette and smokeless merchandise represents a significant regulatory challenge for the FDA. Nicotinamide doesn't have nicotinic receptor agonist action and is thought to work as a sedative at significant dosages6. The promises created by Nicotine River, ECBlend, and various se